Maxim Biomedical Inc. Receives EUA for New ClearDetect™ COVID-19 Antigen Home Test

Trending...
ROCKVILLE, Md., Jan. 25, 2022 /PRNewswire/ -- On January 19, 2022, Maxim Biomedical (MaximBio) received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for their new ClearDetect™ COVID-19 Antigen Home Test (ClearDetect™). The at-home diagnostics market is growing rapidly and is expected to value over USD 7.6 billion and register a CAGR of over 5.4% by the end of 2028.  MaximBio designed, tested, and will manufacture their new assay in the United States to help meet this growing demand for home testing.

More on Marylandian
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on Marylandian